Study to evaluate the performance of SuperSonic Imagine’s ShearWaveTM Elastography for the non-invasive assessment of liver fibrosis severity in patients suffering from chronic Hepatitis B infection
SuperSonic Imagine (Paris:SSI) (Euronext: SSI, FR0010526814), the highly innovative ultrasound company, announced completion of enrollment for a large prospective multicenter liver study in China. The study aims at evaluating the performance of SuperSonic Imagine’s real-time ShearWave Elastography (SWE™) for the non-invasive assessment of liver fibrosis in Chinese patients with chronic Hepatitis B infection.
This study led by Prof. Ping Liang from the People’s Liberation Army Hospital (301) in Beijing, has been conducted in 14 locations across China. All of the 400 Hepatitis B patients recruited for the study had an ultrasound exam, including SWE, to measure liver stiffness and guide liver biopsy, as well as a blood test analysis. As the enrollment and examination are now complete, the next step is to analyze the outcome of these exams and evaluate the correlation between SWE measurements and liver fibrosis, and ultimately assess the diagnostic performance of SWE